Major Depressive Disorder
Conditions
Brief summary
The primary object of this study is to confirm the superiority of tianeptine compared to escitalopram on effects that improves subjective and objective cognitive impairments in patients suffering from major depressive disorder.
Detailed description
Along with depressive symptoms, subjective and objective cognitive impairments are frequently complained by the patients with major depressive disorder. Tianeptine acts on glutamate system and is known as a promising drug for improving cognitive impairment. The present study aims to confirm the superiority of tianeptine compared to escitalopram on effects that improves subjective and objective cognitive impairments after a 12-week treatment in patients suffering from major depressive disorder.
Interventions
DRUGTianeptine
week1 : 25mg/day q.d., week2: 37.5mg/day b.i.d. (12.5mg 1T, 12.5mg 2T
DRUGEscitalopram
week1 : 5mg/day q.d., week2: 10mg/day q.d.
Sponsors
Samsung Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients fulfilling DSM-IV-TR(American Psychiatric Association, 4thedition, 2000) criteria for Major Depressive Disorder diagnosis 2. The male or female patients aged more than 40 years 3. Patients able to hand in written informed consent before his/her participation in this clinical study 4. Women of childbearing potential with negative pregnancy test during screening phase and entire study period (during entire study period, able to clearly agree with effective contraception such as contraceptive pill, progesterone injection, levonorgestrel implant, estrogen ring, transdermal contraceptive agent, intra-uterine contraceptive device, sterilization operation of husband, and double contraceptive method (e.g. combination of condom, pessary, spermicide, etc. )) 5. Patients who have subjective cognitive impairment, or who have objective cognitive impairment (MMSE ≤26) without subjective cognitive impairment 6. HAM-D(17-items) total score ≥ 16
Exclusion criteria
1. Patients meeting more than one following patient characteristics 1. Patients fulfilling DSM-IV-TR current or past diagnosis of any psychiatric disorders other than major depressive disorder (i.e. manic or hypomanic episode, schizophrenia, delirium, dementia, eating disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, major depressive disorder with psychotic features, mental retardation, organic brain disorder, or psychiatric disorders due to general medical condition, according to DSM-IV-TR) 2. Patients with any substance-related disorder (excluding nicotine) within the past 12 months, as defined in DSM-IV-TR 3. Patients with a history or presence of any neurological disorders (e.g. multiple sclerosis, seizure, etc.) 4. Patients with any axis II disorder that prone to interfere with the evaluation of the study 2. Patients with a history or presence of any hypersensitivity to tianeptine, escitalopram or other drugs 3. Patients who receive formal psychotherapy (e.g. cognitive behavioral therapy, insight-oriented psychoanalysis, interpersonal therapy, etc.) and who have a plan for getting psychotherapy 4. Patients with any clinically significant abnormality (e.g. hepatic failure, renal failure, cardiovascular disorder, respiratory disorder, gastrointestinal disorder, endocrine disorder, neurological disorder, inflammatory disorder, neoplasm, metabolic disorder, etc.) 5. Patients who have abnormal ECG and a significant disease according to the investigator's judgment 6. Patients with any chronic liver or kidney disease 7. Patients with a family history of long QT syndrome 8. Patients previously not responders to tianeptine or escitalopram in the treatment of major depressive disorder 9. Patients who have a suicide risk according to the investigator's judgment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in Hamilton Rating Scale for Depression(HAM-D)score from baseline | followed up to 2,4,8,12 weeks from baseline |
| Changes in Korean version-California Verbal Learnign Test(K-CVLT) total score from baseline | followed up to 4,8,12 weeks from baseline |
| Changes in Visual Continuous Performance Test(CPT) total score from baseline | followed up to 4,8,12 weeks from baseline |
| Changes in Raven Progressive Matrices(RPM) total score from baseline | followed up to 4,8,12 weeks from baseline |
Secondary
| Measure | Time frame |
|---|---|
| Change in Sexual Function Scale | followed to 2,4,8,12 weeks from baseline |
| Changes in Clinical Clinical Global Impression- improvement(CGI-I) | followed to 2,4,8,12 weeks from baseline |
| Change in Remission Rate from baseline | followed to 12 weeks from baseline |
| Change in Clinical Global Impression- severity(CGI-S) | followed to 2,4,8,12 weeks from baseline |
| Change in Response Rate from baseline | followed to 12 weeks from baseline |
| Changes in Hamilton Rating Scale for Anxiety(HAM-A) score from baseline | followed to 2,4,8,12 weeks from baseline |
| Change in Mini-Mental status examination(MMSE) total score from baseline | followed to 4,8,12 weeks from baseline |
Countries
South Korea
Outcome results
None listed